In 2017, SLAS’s two scientific journals will begin their 22nd year of publication with new names and taglines! The journal we’ve known as the Journal of Biomolecular Screening (JBS) will become SLAS DiscoveryTM (Advancing Life Sciences R&D); and the journal we’ve known as the Journal of Laboratory Automation (JALA) will become SLAS TechnologyTM (Translating Life Sciences Innovation).
If a tree falls in a forest and no one is around to hear it, does it make a sound? Similarly, if an innovator has a good idea but no means of spreading the word, can the idea move forward to successful implementation? The SLAS Innovation AveNEW program gives life sciences discovery and technology start-up companies a forum to put their good ideas in front of the global community for collaborative interaction and exposure – and a fighting chance for success in the marketplace.
Meet the first SLAS Graduate Education Fellowship Grant recipient: A keen collaborator who wants practical, yet complicated, science – such as microfluidics – to be more user-friendly. An engaging educator who helps high school students find the joy of discovery. A tireless innovator whose pursuits in high-throughput screening will benefit from the generous funding of the SLAS grant.
It has been five years since the SLAS Electronic Laboratory Neighborhood (SLAS ELN) e-zine began bringing to life the people behind the science and technology that drive the SLAS life sciences community forward. The SLAS ELN is the place to learn more about like-minded colleagues and their personal and professional achievements.
New treatments for central nervous system (CNS) disorders are urgently needed, yet many companies have scaled back their work in this area, citing “high costs, lengthy development times and low success rates,” according to an editorial in a new Journal of Biomolecular Screening (JBS) Special Issue on Innovative Screening Methodologies to Identify New Compounds for the Treatment of Central Nervous System Disorders. Novel screening approaches could help turn the tide.
As you likely have heard, the SLAS Graduate Education Fellowship Grant program recently became real when Erik M. Werner, a Ph.D. candidate from the University of California, Irvine, was proudly named the recipient of our first $100,000 grant award. This announcement follows years of thoughtful planning and financial stewardship by members of the SLAS Board of Directors, SLAS Americas Council and the SLAS Awards and Grants Committee.
Brian Buckley likes a hands-on challenge no matter where he’s working – in his woodshop building a bookcase, in the lab trouble-shooting an assay or with a committee constructing career development programs for newcomers to life sciences discovery and technology.
2016 SLAS Innovation Award winner Shana Kelley was a graduate student at Cal Tech when a basic science project serendipitously yielded a technique for identifying single nucleotide mismatches in DNA—i.e., disease-related mutations. “It just popped out of the basic science we were doing and I thought, ‘hmmm, that’s interesting….,’” she recalls.
It will be with much respect and appreciation that SLAS bids farewell to CEO Gregory F. Dummer, CAE, on June 30. Greg’s vision and leadership guided the creation and growth of SLAS into the world’s leading nonprofit membership society devoted exclusively to serving the life sciences discovery and technology community.
This editorial from JALA Editor-in-Chief Edward Kai-Hua Chow on the JALA Special Issue on High-Throughput Imaging Technologies is reprinted with permission of the Journal of Laboratory Automation.
"I really like the European Union's definition of precision medicine, which is the right therapy for the right patient at the right dose at the right time," said Jennifer Harris, director of drug discovery biology at the Genomics Institute of the Novartis Research Foundation (GNF). "It's not only about getting the right drug to the patient, it's also making sure that the drug is delivered in a way that's going to be safe and effective as well."
Serving as guest editor for JALA or JBS expands a scientist's areas of expertise, builds upon innate curiosity and develops a professional network that is built on knowledge exchange and mutual respect. Joe Olechno and Jonathan Wingfield found their recent guest editor experiences personally rewarding and well worth their time and effort.
SLAS2016 Drug Target Strategies Track Chair Michelle Arkin, Ph.D., likes a good puzzle. Not only does she enjoy deciphering complicated connections and matching up contrasting ideas, she refers to it as her "personality super power."
Somewhere in a nearby lab or on an exhibition floor is a technology that some research scientists know about, but might not embrace in their daily work in drug discovery. Adapting its use by pairing it with other technologies opens a world of potential that is currently examined in a special issue of the Journal of Biomolecular Screening (JBS).
Who is behind the science and technology that is winning awards at SLAS2016? Six podcasts offer keen insight into innovative minds.
"I like to work on projects and products that are revolutionary as opposed to evolutionary—things that drastically change what scientists can do," says Joe Olechno, Ph.D. of Labcyte Inc. (Sunnyvale, CA, USA), a guest editor of the JALA special issue, Advancing Scientific Innovation with Acoustic Droplet Ejection. "So when I was asked 12 years ago to market an instrument that moves things with sound, and could really make a difference in the lab, I was intrigued and excited."
The newest members of the SLAS Board of Directors have experienced personally what the Society can do to enrich one's career and support individual innovators who seek to reshape the world through scientific ingenuity. They are fully committed to ensuring that SLAS continues to lead the way for many years to come.
Adventurer, scientist, bridge builder: Several titles define SLAS member Melissa Crisp, Ph.D., and her passion for nature, scientific research and helping newcomers find their footing in industry.
Increasing drug resistance and recent cancer stem cell research have revealed a critical set of potent cancer cells that continue to wreak havoc on patients even when the majority of proliferating cells have been eliminated by effective therapies. But finding ways to better understand these cellular subsets and how they respond to treatment in individual patients remains a challenge, according to Tiffany (TJ) Chen, Ph.D., director of Informatics at Cytobank and a researcher at Stanford University.